Treatment-relatedmortality with everolimus in cancer patients

Oncologist

Volumn 19, Issue 6, 2014, Pages 661-668

  Wesolowski, Robert ^a   Abdel Rasoul, Mahmoud ^a   Lustberg, Maryam ^a   Paskell, Maria ^a   Shapiro, Charles L ^a   Macrae, Erin R ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adverse events; Cancer; Everolimus; Meta analysis; Mortality

Indexed keywords

EVEROLIMUS; EXEMESTANE; LETROZOLE; OCTREOTIDE; PACLITAXEL; PLACEBO; TAMOXIFEN; PROTEIN KINASE INHIBITOR; RAPAMYCIN;

ANGIOMYOLIPOMA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CARCINOID SYNDROME; CARDIOPULMONARY ARREST; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONVULSION; DEATH; DRUG DOSE TITRATION; DRUG FATALITY; DRUG TOLERABILITY; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER FAILURE; LUNG EMBOLISM; LYMPHANGIOLEIOMYOMATOSIS; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SEPSIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUBEROUS SCLEROSIS; TUMOR BLEEDING; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; MORTALITY; NEOPLASMS; PATHOLOGY; PATIENT;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVEROLIMUS; HUMANS; NEOPLASMS; PATIENTS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 84901929180     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0355     Document Type: Article

References (40)

1. Afinitor (everolimus) tablets for oral administration [prescribing information] (August 2012) East Hanover, NJ: Novartis Pharmaceuticals Corporation.
2. NCI Guidelines for Investigators. Available at http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/aeguidelines.pdf. Accessed August 4, 2013.
3. Heron M, Hoyert DL, Murphy SL et al. Deaths: Final data for 2006. Natl Vital Stat Rep 2009;57: 1-134.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279:1200-1205.
5. Mol L, Koopman M, Ottevanger PB et al. A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer. Ann Oncol 2010;21: 415-418.
6. Seruga B, Sterling L, Wang L et al. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011;29:174-185.
7. Choueiri TK, Je Y, Sonpavde G et al. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol 2013;24:2092-2097.
8. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17: 1-12.
9. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. J Clin Epidemiol 2009;62:1006-1012.
10. Cancer Therapy Evaluation Program. Available at http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm. Accessed August 4, 2013.
11. Yusuf S, Peto R, Lewis J et al. Beta blockade during and aftermyocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-371.
12. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-1375.
13. Bradburn MJ, Deeks JJ, Berlin JA et al. Much ado about nothing: A comparison of the performanceofmeta- analytical methodswith rare events. Stat Med 2007;26:53-77.
14. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
15. Harbord RM, Higgins JP. Meta-regression in Stata. Stata J 2008;8:493-519.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
17. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
18. Review Manager (RevMan) [computer program]. Version 5.2. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
19. Van Cutsem E, Yeh KH, Bang YJ et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012;30(suppl 4):LBA3a.
20. Yardley DA, Bosserman LD, Peacock NW et al. Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI). J Clin Oncol 2012; 30(suppl):108a.
21. Jonasch E, Corn PG, Pagliaro LC et al. Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients. J Clin Oncol 2013; 31(suppl): 4517a.
22. O'Regan R, Ozguroglu M, Andre F et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumabresistant, advanced breast cancer (BOLERO-3). J Clin Oncol 2013; 31(suppl):505a.
23. Bernadou G, Rezai K, Merlin JL et al. Trastuzumab (T) and everolimus (E) pharmacokinetics (PK) in HER2 positive (1) primary breast cancer (BC) patients (pts): Unicancer RADHER trial results. J Clin Oncol 2013; 31(suppl).
24. Ravaud A, Barrios CH, Alekseev BY et al. Randomized phase II study of first-line everolimus plus bevacizumab (E1B) versus interferona-2a plus bevacizumab (I1B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results. J Clin Oncol 2013; 31(suppl):4576a.
25. Motzer RJ, Barrios CH, Kim TM et al. Record-3: Phase II randomized trial comparing sequential firstline everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31(suppl):4504a.
26. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256-4265.
27. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
28. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
29. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-2637.
30. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 2012;366:520-529.
31. von Minckwitz G, Eidtmann H, Loibl S et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011;22:301-306.
32. Huober J, Hanusch C, Fasching PA et al. Neoadjuvant chemotherapy of paclitaxel with or without Rad001: Results of the non-responder part of the GEPARQUINTO study (GBG 44). Cancer Res 2011;71(suppl 3):S3-6.
33. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-132.
34. Bissler JJ, Kingswood JC, Radzikowska E et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817-824.
35. Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718-2724.
36. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001;7: 473-484.
37. Abraham RT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998;10:330-336.
38. Cho D, Signoretti S, Regan M et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13(suppl 2):758s-763s.
39. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47:1287-1298.
40. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 2011;305:487-494.